Pfizer's Ibrance clears first hurdle to early access in U.K.

Pfizer's ($PFE) new cancer standout, Ibrance, has taken its first step toward joining the U.K.'s Early Access to Medicines program, winning the "promising innovative medicine" tag from the country's Medicines and Healthcare Regulatory Agency. Since scoring a quick FDA approval last February, the breast cancer-fighter--green-lighted for patients with tumors that are estrogen-receptor-positive but HER2-negative--has been tearing it up in the marketplace. In Q3, Ibrance netted $230 million in sales, burying the $195 million analysts expected. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.